Correlations between Immune Response and Etiopathogenic Factors of Medication-Related Osteonecrosis of the Jaw in Cancer Patients Treated with Zoledronic Acid

• Published in: International journal of molecular sciences 2023-09, Vol.24 (18), p.14345
• Main Authors: Ciobanu, George Adrian, Mogoantă, Laurențiu, Popescu, Sanda Mihaela, Ionescu, Mihaela, Munteanu, Cristina Maria, Staicu, Ionela Elisabeta, Mercuț, Răzvan, Georgescu, Cristian Corneliu, Scrieciu, Monica, Vlad, Daniel, Camen, Adrian
• Format: Article
• Language: English
• Subjects: Acids; Analysis; B cells; Bisphosphonates; Bones; Cancer; Cancer patients; Disease susceptibility; Gum disease; Hypertension; Immune response; immunohistochemical markers; Infections; Intervention; Lymphocytes; Medical research; Medicine, Experimental; Metastasis; MRONJ; Necrosis; Patients; Phosphonates; Prostate; T cells; Zoledronic acid
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms241814345

Impairment of the immune response in MRONJ (medication-related osteonecrosis of the jaws) is one of the still unclear etiopathogenic mechanisms of this condition encountered in cancer patients treated with bisphosphonates, with negative effects on the patient’s quality of life. The aim of the present study was to correlate the immune response with etiopathogenic factors via immunohistochemical evaluation of the maxillary tissues in zoledronic acid osteonecrosis. The retrospective study included a group of 51 patients with various types of cancers, diagnosed with stage 2 or 3 MRONJ at zoledronic acid and treated surgically. Immunohistochemical expressions of αSMA, CD3, CD4, CD8, CD20, CD79α, CD68, CD204, and tryptase were evaluated. Immunohistochemical markers expressions were statistically analyzed according to the duration of the treatment, the trigger factor, the location of the MRONJ, and the healing status. Analysis of the immune response included T lymphocytes, B lymphocytes, plasma cells, macrophages, and mast cells. The duration of treatment significantly influenced the immunohistochemical expression of most markers (p < 0.05). For an increasing trend in treatment duration, a decreasing trend in marker score was observed, suggesting an inverse correlation. The expression of the markers was different depending on the trigger factor, on MRONJ localization (maxilla/mandible), and the healing status, being more intense in patients cured per primam compared to those who had relapses. The patient’s immune response was negatively influenced by the duration of the treatment, the trigger factor, the location of the lesion in the mandible, and the recurrence of MRONJ.